1. A non-beta-lactam antibiotic inhibitor for enterohemorrhagic Escherichia coli O104:H4.
- Author
-
Wang, Haoqi, Jayaraman, Arul, Menon, Rani, Gejji, Varun, Karthikeyan, R., and Fernando, Sandun
- Subjects
- *
ESCHERICHIA coli O157:H7 , *BETA lactam antibiotics , *DRUG resistance in bacteria , *BORONIC acids , *ESCHERICHIA coli , *PENICILLIN-binding proteins - Abstract
The overuse of antibiotics has caused an increased prevalence of drug-resistant bacteria. Bacterial resistance in E. coli is regulated via production of β-lactam-hydrolyzing β-lactamases enzymes. Escherichia coli O104: H4 is a multi-drug resistant strain known to resist β-lactam as well as several other antibiotics. Here, we report a molecular dynamic simulation–combined docking approach to identify, screen, and verify active pharmacophores against enterohemorrhagic Escherichia coli (EHEC). Experimental studies revealed a boronic acid cyclic monomer (BACM), a non-β-lactam compound, to inhibit the growth of E. coli O104: H4. In vitro Kirby Bauer disk diffusion susceptibility testing coupled interaction analysis suggests BACM inhibits E. coli O104:H4 growth by not only inhibiting the β-lactamase pathway but also via direct inhibition of the penicillin-binding protein. These results suggest that BACM could be used as a lead compound to develop potent drugs targeting beta-lactam resistant Gram-negative bacterial strains. Key messages: • An in silico approach was reported to identify pharmacophores against E. coli O104: H4. • In vitro studies revealed a non-β-lactam compound to inhibit the growth of E. coli O104: H4. • This non-β-lactam compound could be used as a lead compound for targeting beta-lactam strains. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF